Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec 21;21(24):9768.
doi: 10.3390/ijms21249768.

Assessment of Endothelial Injury and Pro-Coagulant Activity Using Circulating Microvesicles in Survivors of Allogeneic Hematopoietic Cell Transplantation

Eleni Gavriilaki  1   2 , Ioanna Sakellari  1 , Panagiota Anyfanti  2 , Ioannis Batsis  1 , Anna Vardi  1 , Zoi Bousiou  1 , Antonios Lazaridis  2 , Barbara Nikolaidou  2 , Ippokratis Zarifis  2 , Marianna Masmanidou  1 , Efthalia Yiannaki  3 , Dimitra Markala  3 , Achilles Anagnostopoulos  1 , Stella Douma  2 , Eugenia Gkaliagkousi  2
Affiliations

Assessment of Endothelial Injury and Pro-Coagulant Activity Using Circulating Microvesicles in Survivors of Allogeneic Hematopoietic Cell Transplantation

Eleni Gavriilaki et al. Int J Mol Sci. .

Abstract

(1) Background: survivors of allogeneic hematopoietic cell transplantation (alloHCT) suffer from morbidity and mortality due to cardiovascular events. We hypothesized that vascular injury and pro-coagulant activity are evident in alloHCT survivors without existing alloHCT complications or relapse. (2) Methods: we enrolled consecutive adult alloHCT survivors without established cardiovascular disease and control individuals matched for traditional cardiovascular risk factors (January-December 2019). Circulating microvesicles (MVs) of different cellular origins (platelet, erythrocyte, and endothelial) were measured by a standardized flow cytometry protocol as novel markers of vascular injury and pro-coagulant activity. (3) Results: we recruited 45 survivors after a median of 2.3 (range 1.1-13.2) years from alloHCT, and 45 controls. The majority of patients suffered from acute (44%) and/or chronic (66%) graft-versus-host disease (GVHD). Although the two groups were matched for traditional cardiovascular risk factors, alloHCT survivors showed significantly increased platelet and erythrocyte MVs compared to controls. Within alloHCT survivors, erythrocyte MVs were significantly increased in patients with a previous history of thrombotic microangiopathy. Interestingly, endothelial MVs were significantly increased only in alloHCT recipients of a myeloablative conditioning. Furthermore, MVs of different origins showed a positive association with each other. (4) Conclusions: endothelial dysfunction and increased thrombotic risk are evident in alloHCT recipients long after alloHCT, independently of traditional cardiovascular risk factors. An apparent synergism of these pathophysiological processes may be strongly involved in the subsequent establishment of cardiovascular disease.

Keywords: allogeneic hematopoietic cell transplantation; microvesicles; pro-coagulant activity; vascular injury.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Gratwohl A., Pasquini M.C., Aljurf M., Atsuta Y., Baldomero H., Foeken L., Gratwohl M., Bouzas L.F., Confer D., Frauendorfer K., et al. One million haemopoietic stem-cell transplants: A retrospective observational study. Lancet. Haematol. 2015;2:e91–e100. doi: 10.1016/S2352-3026(15)00028-9. - DOI - PubMed
    1. Sakellari I. New Insights in Hematopoietic Cell Transplantation. Volume 9 Research Signpost; Thiruananthapuram, India: 2010. Hematopoietic stem cell transplantation: Historical perspectives.
    1. Chow E.J., Wong K., Lee S.J., Cushing-Haugen K.L., Flowers M.E., Friedman D.L., Leisenring W.M., Martin P.J., Mueller B.A., Baker K.S. Late cardiovascular complications after hematopoietic cell transplantation. Biol. Blood Marrow Transpl. J. Am. Soc. Blood Marrow Transpl. 2014;20:794–800. doi: 10.1016/j.bbmt.2014.02.012. - DOI - PMC - PubMed
    1. Bhatia S., Francisco L., Carter A., Sun C.L., Baker K.S., Gurney J.G., McGlave P.B., Nademanee A., O’Donnell M., Ramsay N.K., et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: Report from the Bone Marrow Transplant Survivor Study. Blood. 2007;110:3784–3792. doi: 10.1182/blood-2007-03-082933. - DOI - PMC - PubMed
    1. Chow E.J., Mueller B.A., Baker K.S., Cushing-Haugen K.L., Flowers M.E., Martin P.J., Friedman D.L., Lee S.J. Cardiovascular hospitalizations and mortality among recipients of hematopoietic stem cell transplantation. Ann. Intern. Med. 2011;155:21–32. doi: 10.7326/0003-4819-155-1-201107050-00004. - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources